Kornimate/medical-research-clean huggingface dataset:
resiliency in patients undergoing radical cystectomy for bladder cancer

Conditions: Bladder Cancer

Summary: this is a prospective cross-sectional survey-based study composed of both a retrospective chart review and 3-series patient survey. this study will help elicit potential areas throughout the perioperative course of radical cystectomy to improve patient resilience and quality of life, providing opportunity for future interventional studies.

this is a prospective cross-sectional survey-based study composed of both a retrospective chart review and 3-series patient survey. this study will help elicit potential areas throughout the perioperative course of radical cystectomy to improve patient resilience and quality of life, providing opportunity for future interventional studies. primarily, the study will evaluate health related quality of life and resiliency in patients throughout the perioperative course of a radical cystectomy for bladder cancer. the primary objective will be the correlation of the connor-davidson resilience scale (cd-risc-25) and the functional assessment of cancer therapy-bladder-cystectomy (fact-bl-cys) score. patients will be identified and undergo consent and baseline assessments, including completion of surveys prior to their cystectomy. a retrospective chart review will also be completed to record information regarding patient's cancer stage, treatment status, diagnosis date, insurance type, and related medical conditions and medications. data from retrospective chart review will be collected and recorded in a secure redcap database for all eligible patients. subsequent surveys will be administered again at approximately 10-30 days postoperatively, as well as 60-120 days postoperatively.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of bladder cancer * patients electing to undergo radical cystectomy as treatment * ≥ 18 years of age * able to speak and read english * willing and able to provide informed consent * functioning telephone number or access to one exclusion criteria: * patients opting to not undergo radical cystectomy * minors
peripheral facilitated antegrade steering technique in chronic total occlusions

Conditions: Chronic Total Occlusion

Summary: study of the bridgepoint medical system in the crossing of chronic total occlusions of the lower extremities.


Eligibility criteria:
inclusion criteria: * suitable candidate for non-emergent, peripheral angioplasty * documented de-novo or restenotic peripheral cto lesion with timi 0 flow for at least 90 days and satisfactory distal vessel visualization (collateral supply) * limb ischemia or claudication, rutherford class i-iii (grade 1-5) caused by the occluded artery exclusion criteria: * intolerance to aspirin or a neutropenic response to ticlopidine or clopidogrel * appearance of thrombus or intraluminal filling defects * peripheral intervention in the target limb within two weeks of the procedure * renal insufficiency (serum creatinine of \> 2.3 mg/dl) * contraindication to a peripheral artery intervention * participation in another investigational protocol
open-angle glaucoma subjects on one ocular hypotensive medication randomized to treatment with two trabecular micro-bypass stents or selective laser trabeculoplasty

Conditions: Open-angle Glaucoma

Summary: evaluation of intraocular pressure (iop) lowering effect of two istent stents versus a slt procedure in subjects with open-angle glaucoma on one ocular hypotensive medication.

evaluation of intraocular pressure (iop) lowering effect of two istent stents versus a slt procedure in subjects with open-angle glaucoma on one ocular hypotensive medication.

Eligibility criteria:
inclusion criteria: * phakic study eye or study eye with a posterior chamber intraocular lens (pc-iol) * primary open-angle glaucoma (including pseudoexfoliative) exclusion criteria: * aphakic or pseudophakic with anterior chamber iols (ac-iols) (study eye) * prior stent implantations (study eye)

Keywords: open angle glaucoma pseudoexfoliative glaucoma
global utilization and registry database for improved heart preservation

Conditions: Heart Diseases; Heart Failure; Heart Defects, Congenital

Summary: the primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving heart transplants using donor hearts transported via the sherpapak cts system. these results will be compared to outcomes of retrospective patients whose hearts were transported with the previous standard method.

this study is a registry study collecting data both retrospectively from patients already transplanted and prospectively from consecutively enrolled patients for heart transplantation. the study is a chart review study. ongoing eligible recipients will undergo heart transplantation according to standard practices at each participating institution. this study will be conducted at an estimated 25 institutions globally and will have about up to 3000 patients. subjects will be followed from transplant through one-year post-transplantation (i.e., 24 hours post-transplant, discharge, 30-days, 1-year, 2-years, 3-years, 4-years, 5-years). guardian provides critical and contemporary data on patient outcomes, with additional insight into risk factors and patient-related indices. both donor and recipient information along with procedural details (including transportation) will be collected to provide information for major discrete endpoints such as death, primary graft dysfunction, right ventricular dysfunction, cpb weaning, inotrope use, cav diagnosis, rejection, and survival. information about re-hospitalizations and re-transplantations is vital to address the integrated endpoint of days alive out of hospital, which is particularly relevant for this patient population. in addition, the number of in-hospital days and icu time is closely tracked as the major resource utilized, after the initial transplant.

Eligibility criteria:
inclusion criteria: * donor and donor hearts matched to the prospective recipient based upon institutional medical practice * registered male or female primary heart transplant candidates including pediatric candidates exclusion criteria: * donor and donor hearts that do not meet institutional clinical requirements for transplantation * when safe connection with the aorta cannot be made, e.g., due to lack of enough length of the aortic root * patients who are incarcerated persons (prisoners) * patients who have had a previous organ transplant
bortezomib and low dose cytarabine in the treatment of high-risk myelodysplastic syndromes

Conditions: Myelodysplastic Syndromes

Summary: we are evaluating the efficacy of the association of low dose cytarabine in association with bortezomib in the treatment of patients diagnosed with high risk myelodysplastic syndromes. our aim is to decrease transfusion requirements and if possible induce a complete or at least a partial remission.

four cycles of treatment are proposed at 28 day intervals in an ambulatory setting cycle 1 : * cytarabine 10 mg /m2/day subcutaneous injection for 14 days * bortézomib 1,5mg/m2 days 1,4,8,11 cycles 2, 3, 4 : * cytarabine 20 mg /m2/j subcutaneous injections for 14 days * bortézomib 1,5mg/m2 days 1,4,8,11 bone marrow aspirates are evaluated just before the first cycle, after the second and after the fourth cycles responding patients may continue the treatment for 2 further cycles

Eligibility criteria:
inclusion criteria: * mds with ipss scores int-2 or high * life expectancy greater than 6 months * no other available treatment options exclusion criteria: * mds with ipss scores low or int-1 * \> 30% bone marrow blasts * clinical neuropathy of greater than grade 2 * ecog score 3 or 4 * creatinine clearance of \< 30 ml/min * lmmc * pregnant patients or lactating mothers * patients having received intensive chemotherapy in the 3 months prior to inclusion * patients with uncontrolled pulmonary, cardiac, neurological, gastro-intestinal or genito-urinary disorders

Keywords: myelodysplastic syndromes ipss int-2 and high risk bortezomib low dose cytarabine bone marrow diseases
measuring fatigue in triage: a pilot study

Conditions: Fatigue

Summary: the purpose of this study is to determine how the length of a triage shift (i.e. 4 vs., 8 vs., 12 hours) affects fatigue levels among triage nurses in the emergency department (ed).

this will be a prospective descriptive pilot study. the demographic data forms and the adapted reaction questionnaires will be administered to subjects via pen and paper after obtaining informed consent at the conclusion of the staff meetings. they will be collected by administrative assistants and placed into a secure drop box, located in the study coordinator's office. only the assigned unique subject id will be used on all data forms. during the ed triage data collection phase, administrative assistants will be on-site to give triage nurses the fatigue questionnaire. it will be completed using pen and paper every two hours, with subjects cued to complete the questionnaire by administrative assistants. after the subject completes the survey, he/she will place it in an envelope and hand it to the administrative assistant who will place it into a secured drop box, located in a study coordinator's office. no phi or identifying data will be on the completed surveys. each participant will only use the previously assigned unique subject id, known only to the study coordinator \& co-pis, \& pi. the key to the unique id will be kept in a locked secure file accessible only by the study coordinator and co-pi. data will be collected over a total of six 24-hour periods. the first 24-hour data collection period will take place on a high volume day (monday) in which triage nurses will be assigned to 12-hour triage shifts. the second 24-hour data collection period will take place on a low volume day (sunday) in which triages nurses will again be assigned to 12-hour triage shifts. the third 24-hour data collection period will take place on a high volume day (monday) in which nurses will be assigned to 8-hour triage shifts. the fourth 24-hour data collection period will take place on a low volume day (sunday) in which nurses will again be assigned to 8-hour triage shifts. the fifth 24-hour data collection period will take place on a high volume day (monday) in which nurses will be assigned to 4-hour triage shifts. the sixth 24-hour data collection period will take place on a low volume day (sunday) in which nurses will again be assigned to 4-hour triage shifts.

Eligibility criteria:
inclusion criteria: -eligible nurses include those who: * are regularly assigned to triage * have demonstrated competency by passing the esi triage class. (nurses in both emergency departments are required to attend a course in emergency severity index (esi), as well as demonstrate competency through esi testing prior to being assigned to work in the triage area. before taking the course, a nurse is required to have one year of nursing experience.) exclusion criteria: * none
better before - better after: prehabilitation program for older patients awaiting total hip replacement

Conditions: Arthritis of Hip

Summary: health professions need to prepare for the large increase in the number of older people with oa requiring health services including tja surgery. older age and poor physical function influences the postoperative prognosis of tja. at discharge from hospital after tja, studies have shown that gait speed can be severely impaired among older patients. the investigators hypothesize that an exercise program of 6-12 weeks will be beneficial for patients that are undergoing tja.

more than 300.000 norwegians above 20 years of age have osteoarthritis (oa) . there has been a significant increase in the prevalence of oa over the decades. in the united states knee oa affects 19% of adults aged 45 years or older. oa is associated with an extensive high economic and personal burden, largely attributable to the effects of disability, comorbid disease, and the expense of treatment. given the aging population, the number of total joint arthroplasty procedures (tja) for hip and knee is likely to increase substantially. in light of poor physical function prior to surgery among older patients and the likelihood of an added decrease during hospitalization and risk of poorer outcome after surgery, it is hypothesised that prehabilitation (preoperative exercise) would improve outcomes after surgery, however evidence for its efficacy is still lacking

Eligibility criteria:
inclusion criteria: * participants 70 years or older living at home with residential address in the county of oslo or akershus scheduled for elective primary total hip replacement due to end-stage osteoarthritis. * harris hip score \>60. * participants must also be capable in norwegian and be able to follow exercise sessions. exclusion criteria: * patients with known rheumatoid arthritis or medical contraindications or those who are scheduled for revision of hip arthroplasty * unable to speak and understand the norwegian language. * patients with neurological disorders affecting gait * medical contraindications for exercise

Keywords: exercise prehabilitation arthritis quality of life osteoarthritis rehabilitation
x-linked hypophosphatemia disease monitoring program

Conditions: X-linked Hypophosphatemia; Hypophosphatemic Rickets

Summary: the objectives of this observational study are to characterize xlh disease presentation and progression and to assess long-term effectiveness and safety of burosumab.

the xlh-dmp is a global, prospective, multicenter, longitudinal, long-term outcomes program for subjects on or off any treatment designed to characterize xlh disease presentation and progression, assess long-term safety and effectiveness of burosumab, as well as prospectively investigate longitudinal change over time across biomarker(s), clinical assessments, and patient/caregiver-reported outcome measures in a representative population. the xlh-dmp will collect demographic, biochemical, physiologic, disease severity, and progression data in patients taking burosumab and those not taking burosumab. in this dmp, patients will only have access to burosumab through authorized prescribed use. the sponsor will not provide any treatments as part of the dmp.

Eligibility criteria:
inclusion criteria: * willing and able to provide informed consent or, in the case of patients under the age of 18 years (or 16 years, depending on the region), provide assent (if required) and informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures. * clinical diagnosis of xlh based on family history, or confirmed phex mutation, or biochemical profile consistent with xlh. * willing and able to comply with the study visit schedule and study procedures. exclusion criteria: * concurrent enrollment in an ultragenyx-sponsored clinical trial is not permitted. * serious medical or psychiatric comorbidity. * less than one year of life expectancy.

Keywords: x-linked hypophosphatemia fibroblast growth factor 23 (fgf23) krn23 xlh hypophosphatemia familial hypophosphatemic rickets fgf23 crysvita
evaluation of the clinical efficacy of moxibustion with regulating yin and yang in the treatment of menopausal obesity

Conditions: Obesity

Summary: this study is designed as a two-dummy randomized controlled trial to evaluate the safety and superiority of yin and yang regulating moxibustion in the treatment of menopausal obese patients.

the study will be a multicenter, randomized, controlled trial, conducted from january 2021 to december 2022, including 216 menopausal obese patients who meet the inclusion criteria. the subjects will be randomly divided into 2 treatment groups: yin and yang regulating moxibustion group and mild moxibustion group. each group of treatment will last for 12 weeks, with a follow-up period of 12 weeks. the main outcome indicator is waist circumference. the secondary outcome indicators include subjects related to obesity, tcm clinical syndrome score and modified kupperman score, weight impact on quality of life scale (iwqol-lite), quality of life assessment health survey summary (sf-36). during the intervention period, adverse events will be recorded.

Eligibility criteria:
inclusion criteria: 1. patients who meet the diagnostic criteria for menopausal syndrome and obesity; 2. patients with bmi≥25 and waist circumference≥80cm; 3. female patients between 40-60 years old; 4. have not taken any hormone drugs or weight loss related drugs in the past 3 months; 5. sign the informed consent and voluntarily accept the intervention methods of this project. exclusion criteria: 1. unexplained vaginal bleeding, or unnatural menopause; 2. have used hormone replacement therapy or other drugs related to this disease in the past 3 months; 3. combined with serious organic diseases, endocrine diseases, heart, liver and kidney, and respiratory diseases; 4. secondary obesity caused by hypothalamic lesions, hypothyroidism, glucocorticoid therapy, etc.; 5. combined with organic uterine diseases, such as polycystic ovary syndrome, malignant tumors, severe cervical erosion, after total hysterectomy, etc.; 6. there are contraindications to moxibustion, such as moxibustion intolerance, skin allergies, scars, and other serious skin diseases; 7. poor compliance and unable to adhere to treatment.

Keywords: menopausal obesity yin and yang regulating moxibustion a randomized controlled trial
modulation of molecular fingerprinting in pediatric sepsis

Conditions: Systemic Inflammatory Response Syndrome

Summary: the goal of this study is to demonstrate the sensitivity and specificity of detecting circulating micro rna (mirna) biomarkers in pediatric septic patients. it will also follow expression and modulation of levels in response to therapy in comparison to current biomarkers.

this study will aid in the evaluation of determining the accuracy of these mirnas in pediatric patients and help in establishing pilot data for additional studies in the future. the testing will include blood samples, urine samples and buccal swabs from patients who meet eligibility at 5 time points to analyze biomarkers. study participants will receive standard of care with antimicrobials and any additional appropriate cardiovascular or respiratory support per the clinical team. the samples will collected and stored at -80 until analysis can be performed. in addition to, during the course of the hospitalization, the enrolled patient will have data collected to calculate severity scores, including updated pediatric risk of mortality (prism iii) scores and simplified therapeutic intervention scoring system(tiss-28) scores. all patient information will be de-identified. a standard procedure manual will be developed detailing the methods for data collection and entry. data will be recorded in a de-identified manner on a microsoft excel database on a secure institutional server by the institutional staff. data will then be analyzed to determine correlation of biomarkers to morbidity and mortality for these patients.

Eligibility criteria:
inclusion criteria: * age 1 through 18 years * patients admitted to the picu with concerns for sepsis or those developing sepsis during their admission to the hospital. * patients must be enrolled int he study from arrival time tot he ed up to 24 hours from the time of initiation of antibiotic therapy for treatment of sepsis or septic shock. * signed informed consent. exclusion criteria: * patients \<1 year of age and greater than 18 years of age.

Keywords: pediatric sepsis
ivabradine to prevent anthracycline-induced cardiotoxicity

Conditions: Neoplasms; Heart Failure; Cardiotoxicity; Chemotherapy Effect; Oncology

Summary: anthracyclines are associated with cardiotoxic effects. previous studies suggest that enalapril, and or carvedilol, protect against cardiovascular effects of these drugs. ivabradine selectively reduces heart rate through inhibition of the cardiac pace maker if channel, thus prolonging the duration of spontaneous depolarization in the sinus node. additionally, ivabradine might preserve myocardial perfusion without negative inotropic effect and probably maintain cardiac contractility despite the reduction of heart rate. ivabradine has been shown to improve outcome in patients with heart failure and angina. the aim of this study is to evaluate whether ivabradine might prevent anthracycline-induced cardiotoxicity.


Eligibility criteria:
inclusion criteria: * age 18-year-old or older; * cancer diagnosis; * chemotherapy with anthracycline; * written informed consent exclusion criteria: * chronic kidney disease (creatinine clearance inferior to 30ml/min/1.73m2) * bradycardia (heart rate less than 60 beats per minute) * atrial fibrilation; * previous diagnosis of heart failure; * pregnancy; * history of previous hypersensibility to the study drug; * participating in another study protocol.
evaluation of the effect the medical team in the delivery room has on pain management during labor.

Conditions: Labor Pain

Summary: in the current study the investigators wish to evaluate the effect the doctors and midwives in the delivery room have on the timing and modality of analgesia chosen by the participants. the participants will be randomly divided into 2 groups. both groups will be advised of the different modalities of analgesia available during labor. one group will be managed in the delivery room the same as if not part of the study, meaning the doctors and midwives will treat the participants the way they usually do regarding analgesia. the second group of participants will not be asked by the doctors and midwives about analgesia at all but will be able to receive analgesia by a modality of choice at the timing of choice.

after explaining to the participants the study and having signed a confirmed consent, participants will receive an extensive explanation regarding the different modalities of analgesia available during labor. after the explanations the participants will be randomly divided into 2 groups: 1. routine management-doctors and midwives will treat the participants the way they usually do regarding analgesia including frequent inquiries about wishes for analgesia. 2. interventional management-participants will not be asked by the doctors and midwives about analgesia at all during labor but will be able to receive analgesia by a modality of choice at the timing of choice after being advised by the medical team. after delivery, participants will fill a questionnaire regarding the experience of labor in general and the relevance of analgesia during labor including the effect the medical team may have had on decision making during labor. medical information regarding visual analogue scale (vas), analgesia modality, cervical conditions, parity etc. will be extracted from patients' electronic files.

Eligibility criteria:
inclusion criteria: * women planned for vaginal delivery. exclusion criteria: * women planned for cesarean section. * women with comorbidities related to pain that may exacerbate during labor.